News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
393 Results
Type
Article (10)
Company Profile (1)
Press Release (382)
Section
Business (68)
Deals (12)
Drug Development (105)
FDA (8)
Job Trends (5)
News (205)
Policy (28)
Tag
Alliances (17)
Antibody-drug conjugate (ADC) (1)
Approvals (9)
Best Places to Work (3)
Biotechnology (1)
Cell therapy (2)
Clinical research (92)
Collaboration (1)
C-suite (1)
Data (5)
Earnings (26)
Editorial (1)
Events (53)
FDA (11)
Funding (7)
Gene therapy (1)
GLP-1 (1)
Healthcare (2)
IPO (7)
Job creations (2)
Legal (2)
Manufacturing (1)
Medical device (4)
Medtech (4)
Mergers & acquisitions (7)
Metabolic disorders (2)
NextGen: Class of 2026 (2)
Obesity (2)
People (21)
Phase 1 (9)
Phase 2 (49)
Phase 3 (37)
Pipeline (4)
Postmarket research (3)
Preclinical (10)
Radiopharmaceuticals (1)
Rare diseases (1)
Real estate (1)
Regulatory (30)
Series B (2)
Startups (4)
Vaccines (3)
Venture capital (3)
Date
Last 30 days (2)
Last 365 days (16)
2026 (6)
2025 (11)
2024 (16)
2023 (8)
2022 (6)
2021 (7)
2020 (10)
2019 (12)
2018 (12)
2017 (24)
2016 (23)
2015 (27)
2014 (27)
2013 (38)
2012 (36)
2011 (34)
2010 (27)
Location
Asia (16)
Australia (3)
California (4)
Canada (1)
China (1)
Europe (35)
Indiana (1)
Massachusetts (11)
Nevada (1)
Northern California (2)
Pennsylvania (1)
South America (1)
Southern California (2)
United States (16)
393 Results for "diagonal therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline
January 8, 2026
·
5 min read
Venture capital
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, EpiBiologics, Beacon Therapeutics and Protege.
January 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Diagonal Therapeutics Appoints John Lee, M.D., Ph.D., as Chief Medical Officer
July 9, 2025
·
4 min read
Press Releases
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
June 19, 2025
·
4 min read
Press Releases
Diagonal Therapeutics Announces Publication of Data Characterizing the Healthcare System Cost and Impact of Hereditary Hemorrhagic Telangiectasia (HHT) in the American Journal of Hematology
July 11, 2025
·
4 min read
Press Releases
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
June 12, 2025
·
5 min read
Genetown
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases
Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched with $128 million in financing.
April 3, 2024
·
4 min read
Press Releases
Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
December 4, 2024
·
4 min read
Press Releases
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
October 8, 2024
·
3 min read
Business
Diagonal Therapeutics Nets $128M for New Approach to Agonist Antibodies
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
April 3, 2024
·
2 min read
·
Kate Goodwin
1 of 40
Next
